St. Gallen 2007: Breast cancer treatment consensus report

Breast Care

Volumn 2, Issue 3, 2007, Pages 130-134

  Harbeck, N ^a   Jakesz, R ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Breast cancer; Chemotherapy Antibody therapy; Endocrine treatment; Targeted therapy

Indexed keywords

ANASTROZOLE; BISPHOSPHONIC ACID DERIVATIVE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; EXEMESTANE; FLUOROURACIL; GONADORELIN DERIVATIVE; LETROZOLE; METHOTREXATE; PACLITAXEL; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB;

BONE DENSITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER SURVIVAL; CLINICAL PRACTICE; CONFERENCE PAPER; HIGH RISK PATIENT; HUMAN; MENOPAUSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVARIECTOMY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 34347358582     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000103629     Document Type: Conference Paper

References (16)

1. Goldhirsch A, Glick JH, Gelber RD, et al.: Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005;16:1569-1583.
2. Goldhirsch A, Coates AS, Gelber RD, et al.: First - select the target: better choice of adjuvant treatments for breast cancer patients. Ann Oncol 2006;17:1772-1776.
3. Fan C, Oh DS, Wessels L, et al.: Concordance among gene expression-predictors for breast cancer. N Engl J Med 2006;355:560-569.
4. Davidson N: Ovarian function suppression in the adjuvant program. Primary Therapy of Early Breast Cancer: 10th International St. Gallen Conference, 2007, oral presentation.
5. Cuzick J: The impact of LHRH agonists on breast cancer recurrence and mortality. 29th San Antonio Breast Cancer Symposium, 2006, oral presentation.
6. Cuzick J, Ambroisine L, Davidson N: Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: A meta-analysis of individual patient data from randomised adjuvant trials. Lancet 2007;369:1711-1723.
7. Goss P: Application of aromatase inhibitors in endocrine responsive breast cancer. Primary Therapy of Early Breast Cancer: 10th International St. Gallen Conference, 2007, oral presentation.
8. Jakesz R, Jonat W, Gnant M, et al.: Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366:455-462.
9. Jonat W, Gnant M, Boccardo F, et al.: Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol 2006;7:991-996.
10. Goss PE, Ingle JI, Martino S, et al.: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Nat Cancer Inst 2005;97:1262-1271.
11. Jakesz R, Greil R, Gnant M, et al.: Extended adjuvant therapy with anastrozole: results from Austrian Breast and Colorectal Cancer Study Group Trial 6A. J Nat Cancer Inst, submitted.
12. Sorlie T, Perou CM, Tibshirani R, et al.: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-10874.
13. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al.: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672.
14. Romond EH, Perez EA, Bryant J, et al.: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-1684.
15. Slamon D: BCIRG 006 II interim analysis. San Antonio Breast Cancer Symposium, 2006, oral presentation.
16. AGO Kommission Mamma: Diagnosis and treatment of patients with primary and metastatic breast cancer: guidelines of the AGO Breast Commission. www.ago-online.org.